Merck hands over $20M in IBD drug target deal with Flagship's Quotient Read more →
Innovent sees path to China approval after eye disease drug matches Eylea in phase 3 Read more →
Fierce Biotech Fundraising Tracker '26: Immutrin's $87M series A; Crossbow targets $77M Read more →
« All Events
February 4, 2025 @ 11:30 am
Presentations from the Olink team on the value of combining genomic and proteomic data for the best insights into human disease and development of new therapeutics, and more. After, enjoy lunch and networking.